{"id":"W4415320736","doi":"10.1016/j.jtha.2025.09.029","title":"Health-related quality of life in adults with hemophilia B after gene therapy with fidanacogene elaparvovec: results from the BENEGENE-2 trial","year":2025,"lang":"en","type":"article","venue":"Journal of Thrombosis and Haemostasis","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada); Thrombosis and Atherosclerosis Research Institute","funders":"Pfizer","keywords":"Quality of life (healthcare); Clinical trial; Health related quality of life; Genetic enhancement; MEDLINE","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001061239,0.0007747185,0.001422521,0.0001699714,0.0002479517,0.001020141,0.0004086366,0.001011129,0.001261344],"category_scores_gemma":[0.001246079,0.000190318,0.001918351,0.0004073595,0.0005926275,0.0005643123,0.000370695,0.001650528,0.0001937406],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005211453,"about_ca_system_score_gemma":0.0003576031,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001121794,"about_ca_topic_score_gemma":0.001711836,"domain_scores_codex":[0.9995164,0.0002537493,0.00002626907,0.0000731549,0.00004860264,0.00008195883],"domain_scores_gemma":[0.9995308,0.0001318979,0.0001561597,0.00003297618,0.00002489403,0.0001231861],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8281811,0.006162509,0.07368212,0.001514872,0.01129683,0.0003141218,0.000209294,0.00141353,0.004703198,0.0005529181,0.004172692,0.06779691],"study_design_scores_gemma":[0.4109,0.135613,0.4297889,0.00050055,0.0124063,0.0005567676,0.0003875865,0.001616455,0.001458402,0.001279123,0.005373171,0.000119585],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892462,0.008432907,0.0001076805,0.0004580244,0.000114873,0.00009096064,0.0006449365,0.00001010993,0.0008944196],"genre_scores_gemma":[0.9935403,0.003207646,0.0001553991,0.0005916486,0.0002255,0.0001692536,0.001522856,0.000004886571,0.0005824565],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001422521,"threshold_uncertainty_score":0.005612493,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0700111764484138,"score_gpt":0.3556926906903589,"score_spread":0.2856815142419451,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}